Please login to the form below

Not currently logged in
Email:
Password:

nusinersen

This page shows the latest nusinersen news and features for those working in and with pharma, biotech and healthcare.

Shock as NICE turns down Biogen’s SMA therapy

Shock as NICE turns down Biogen’s SMA therapy

Spinraza (nusinersen) is the first and so far only drug for the often-fatal genetic disease, but despite approval last year NICE’s review was held back by deliberations over the ... In a statement, NICE said that the evidence showed “a substantial

Latest news

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    95. Ionis (US). Biogen (US). Exercise option . Nusinersen, in phase III for treatment for spinal muscular atrophy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics